Skip to main content
Solasia Pharma K.K. logo

Solasia Pharma K.K. — Investor Relations & Filings

Ticker · 4597 ISIN · JP3436500007 LEI · 529900A8W8K4LULTG564 T Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2021-03-22 Interim / Quarterly Rep…
Country JP Japan
Listing T 4597

About Solasia Pharma K.K.

https://solasia.co.jp/en/

Solasia Pharma K.K. is a specialty pharmaceutical company focused on oncology. The company's business model involves in-licensing promising drug candidates to develop and commercialize them for patients in Asian markets. Its portfolio is centered on addressing unmet medical needs in both cancer treatment and supportive care, aiming to improve patients' quality of life. Key commercialized products include Sancuso® for chemotherapy-induced nausea and vomiting (CINV), DARVIAS® for peripheral T-cell lymphoma (PTCL), and episil® oral liquid, a medical device for pain associated with oral mucositis. The development pipeline includes candidates for treating chemotherapy-induced peripheral neuropathy (CIPN) and colorectal cancer.

Recent filings

Filing Released Lang Actions
訂正四半期報告書－第13期第2四半期(令和2年4月1日－令和2年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Solasia Pharma K.K. under the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, management analysis (MD&A), and corporate information for the second quarter of the fiscal year. Although it is labeled as a 'Correction' (訂正), it constitutes the full interim/quarterly financial report, not merely an announcement of one. Therefore, it is classified as an Interim/Quarterly Report. H1 2020
2021-03-22 Japanese
四半期報告書－第13期第3四半期(令和2年7月1日－令和2年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Solasia Pharma K.K., covering the third quarter of the 13th fiscal period (July 1, 2020, to September 30, 2020). It contains detailed financial statements, management analysis (MDA), and business updates, which aligns with the definition of an Interim/Quarterly Report (IR). Q3 2020
2020-11-13 Japanese
四半期報告書－第13期第2四半期(令和2年4月1日－令和2年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act of Japan. It contains comprehensive financial statements, management analysis (MD&A), and details on shareholding and business operations for the period ending June 30, 2020. As it is a formal, comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2020
2020-08-12 Japanese
四半期報告書－第13期第1四半期(令和2年1月1日－令和2年3月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Solasia Pharma K.K., covering the period from January 1, 2020, to March 31, 2020. It contains detailed financial statements, including the Statement of Financial Position, Statement of Profit or Loss, and Statement of Comprehensive Income, as well as management analysis. This fits the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-05-14 Japanese
有価証券報告書－第12期(平成31年1月1日－令和1年12月31日)
Annual Report Classification · 100% confidence The document is a 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains comprehensive financial statements, management discussion, and corporate information for the fiscal year ending December 31, 2019. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2019
2020-03-30 Japanese
四半期報告書－第12期第3四半期(2019/07/01－2019/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (第３四半期報告書) for Solasia Pharma K.K., covering the period from July 1, 2019, to September 30, 2019. It contains detailed financial statements, including the Consolidated Statement of Financial Position, Statement of Profit or Loss, and Statement of Comprehensive Income, prepared in accordance with IFRS. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. 9M 2019
2019-11-13 Japanese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.